First Drug for MET+ NSCLC Shows High Response Rates First Drug for MET+ NSCLC Shows High Response Rates

Capmatinib, the first drug that targets non-small cell lung cancer (NSCLC) harboring MET mutations, produced impressive responses, especially in treatment-naive patients.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news